Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Astria Therapeutics (ATXS) EBITDA Margin: 2017-2018

Historic EBITDA Margin for Astria Therapeutics (ATXS) over the last 2 years, with Sep 2018 value amounting to 60,080.00%.

  • Astria Therapeutics' EBITDA Margin rose 6286080.00% to 60,080.00% in Q3 2018 from the same period last year, while for Sep 2018 it was -17,186.67%, marking a year-over-year change of. This contributed to the annual value of 26,371.00% for FY2018, which is 3178980.00% up from last year.
  • Astria Therapeutics' EBITDA Margin amounted to 60,080.00% in Q3 2018, which was up 198.77% from 20,109.09% recorded in Q2 2018.
  • In the past 5 years, Astria Therapeutics' EBITDA Margin registered a high of 60,080.00% during Q3 2018, and its lowest value of -2,780.80% during Q3 2017.
  • Its 2-year average for EBITDA Margin is 14,181.14%, with a median of 5,448.03% in 2017.
  • Data for Astria Therapeutics' EBITDA Margin shows a peak YoY skyrocketed of 6,286,080bps (in 2018) over the last 5 years.
  • Over the past 2 years, Astria Therapeutics' EBITDA Margin (Quarterly) stood at -2,198.80% in 2017, then soared by 6,286,080bps to 60,080.00% in 2018.
  • Its last three reported values are 60,080.00% in Q3 2018, 20,109.09% for Q2 2018, and 13,401.75% during Q1 2018.